Ventyx Biosciences
VTYX
VTYX was delisted on the 3rd of March, 2026.
46 hedge funds and large institutions have $619M invested in Ventyx Biosciences in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
62.84% more ownership
Funds ownership: 0% → 62.84% (+63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
+$95M |
| 2 |
TP
Third Point
New York
|
+$81.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$73.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$41.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.7M |
Top Sellers
VTYX Hedge Fund Activity: Q4 2021 in Review
46 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q4 2021, worth a combined $619M.
Buyers outnumbered sellers: 46 funds opened new VTYX positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was venBio Partners, opening a new position worth an estimated $95M.
- 46 institutional investors held Ventyx Biosciences (VTYX) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $619M of Ventyx Biosciences stock for Q4 2021.
- 46 funds opened new Ventyx Biosciences positions in Q4 2021 and 0 closed out, a net change of +46 holders.
- The largest Ventyx Biosciences buyer in Q4 2021 was venBio Partners, an estimated $95M added.
Based on aggregated 13F filings for Q4 2021.